AzTrials
AzTrials

Laser BurnCOLA-BNCT05037916

Comparison of Laser Speckle Contrast Imaging and Laser Doppler Imaging in Burn Patients

An observational study of Laser Burn, run by Maasstad Hospital at 1 site in Netherlands.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Timely and accurate estimation of the surface area and depth of a burn injury is essential for determining an appropriate treatment modality. Inappropriate or inadequate treatment may result in complications and increased societal costs. Read more about this study

Who is it for?
Ages 16 years and older
Conditions the study is for
Laser Burn
What is being tested?
laser speckle contrast imaging device
How many people
50 participants
Where
1 siteNetherlands
Study dates
15 Apr 2019to 12 Mar 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 years and older
  • All sexes
  • Child, Adult, Older adult

Study population: • All consecutive adult patients with acute burn wounds, who are seen within 5 day post burn in the Burn Centre of the Maasstad hospital are eligible to enroll in the study.

Who may be able to join

  • ≥ 16 years old
  • Acute burn wounds admitted in the Burn Centre of the Maasstad hospital
  • Assessment burn wounds with laser Doppler imager

Who cannot join

  • Pregnant
  • Unconscious patients

Trial locations and contacts

1 site in 1 country.

Netherlands1 site
  • Maastad hospital

    Rotterdam, South Netherlands, 3079DZ

Other trials in Netherlands

About this study

Timely and accurate estimation of the surface area and depth of a burn injury is essential for determining an appropriate treatment modality. Inappropriate or inadequate treatment may result in complications and increased societal costs. Burn depth is determined by subjective assessing the characteristics of burn injury. Some objective methods are available (e.g., biopsy and histology, thermography and laser doppler imaging), but these are cumbersome. In assessing burn wounds, laser Doppler imaging (LDI) which has a good correlation with histology, is currently the most widely used and validated noninvasive measurement tool. In addition, it is the only technique that has been approved by the U.S. Food and Drug Administration. However, the use of LDI is accompanied by some disadvantages. The current commercial available LDI device is rather costly, cumbersome and has a poor spatial resolution. Another laser-based technique, laser speckle contrast imaging (LSCI), works with a similar principle and might become an alternative for LDI. LSCI has some advantages over LDI such as higher spatial resolution, much easier to position, no valuable time wasted on setting up the instrument, easy to take several images of burns that have a large surface area and/or much curvature, faster measurements, fraction of the time needed for getting a high-quality measurement, able to follow changes in the perfusion in real time. In contrast to the LDI, the LSCI has not been validated in terms of a diagnostic tool for stratifying the severity of a burn (based on LDI color coding). Consequently, we will compare the LSCI with LDI to improve burn care by providing cheaper, faster and higher resolution imaging technique.

Read the detailed description

After receiving adequate information and when informed consent is signed, patients are included. All patients receive usual care. Within 2-5 days post burn the LSCI and LDI are performed. Ideally, LDI is performed after 2 days, scanning up to 5 days is permitted when patients present later post burn or due to logistic reasons. The wounds are scanned by a trained research physician or nurse, during regular wound care.

8.4 Population base: Measurements of microcirculation with laser-based technique will be initiated upon the ethical consent is approved. Fifty burn patients will be included in the study. All patients will be asked for the existence of any comorbid disease. Once the patient meets the inclusion criteria, he will be eligible for the study.

LSCI and LDI devices will alternately be used to record blood flux. Burn wound including the healthy area 5 cm wider than the borders will be scanned by LDI and LSCI. After completing the data collection, all images will be compared to test the linearity between arbitrary units of LDI and LSCI. Based on the measured blood flux, a color image will be created, based on a color map created in a study on volunteers. Blood flux is calculated by the dedicated software.

Names of the patients will be coded with numbers. Only the main investigator will be aware of who corresponds to which number. Results of Perimed (LSCI) and Moore Devices (LDI) will be analyzed with the software PIMsoft 1.5 (Perimed AB, Järfälla, Sweden), MoorLDI2-BI Burn's Software Version 4.0, respectively. Two investigators will perform the analysis. If one investigator will make the analysis, the other will check the results, as well. Stored data will be extracted and stored coded in the castor study management system en electronic data capture system.

Assessment of microcirculation with the Perimed LSCI Pericam PSI System (Perimed AB, Järfälla, Sweden) Laser Speckle Contrast Imager is used to measure skin perfusion. The system uses a divergent laser beam with a wavelength of 785 nm. Perfusion images are acquired by averaging data from 21 images taken in rapid succession (acquisition time 1 seconds), over 1-minute intervals. A flexible working distance from 10 to 40 cm allows measurement areas up to 24 x 24 cm. Tissue blood perfusion is visualized in real time with a resolution of up to 100 µm/pixel. The system is calibrated according to the manufacturer recommendations. Perfusion images will be further analyzed by calculating mean perfusion levels in regions of interest using PIMsoft 1.5 (Perimed AB, Järfälla, Sweden).

Operating procedures:

  1. Switch on the computer and any peripherals
  2. Switch on the Perimed instrument to be used via the switch on the rear panel
  3. Allow the instrument at least 5 minutes for warm-up
  4. Start the PIMSoft software on computer
  5. Make sure that you allowed the subject at least 20 minutes to rest and acclimatize before the measurement, make sure the subject is in a comfortable position.
  6. Position the instrument head within the recommended measurement distance from the tissue (10-40 cm)
  7. The head should be parallel, and the laser beam perpendicular to the tissue being measured
  8. Set the size of the measurement area by entering the desired width and height in the corresponding text boxes. Select a point density (resolution).
  9. Click on the start button
  10. After recording the image and/or video click on the stop button and finalize the recording
  11. Recorded document is already saved to the computer

Assessment of microcirculation with the Moor LDI

MoorLDI2-BI System (Moor Instruments Ltd., Axminster, Devon, UK) is used to measure skin perfusion. The system uses a divergent laser beam with a wavelength of 633 nm. A flexible working distance from 30 to 100 cm allows measurement areas up to 50 x 50 cm. Scan times are ranging from 40 seconds up to 2 minutes. The scan speed is approximately 4ms/pixel. Tissue blood perfusion is visualized in real time with a maximum image resolution of 256x256 pixels. The system is calibrated according to the manufacturer recommendations. Perfusion images will be further analyzed by calculating mean perfusion levels in regions of interest using MoorLDI2-BI Burn's Software Version 4.0.

Operating procedures:

  1. It is common practice to perform moorLDI2-BI scans after dressings have been removed during routine dressing change. This avoids extra patient discomfort.
  2. Remove dressings (during routine wound management) and any cream (e.g., silver sulphadiazine) to a light smear or better.
  3. Position the patient with due regard to maintenance of a sterile environment for the wound. The wound should be held in a comfortable position so that it can be held reasonably still for the duration of the moorLDI2-BI scan.
  4. The patient should breathe normally during the scan and should avoid coughing or holding breath.
  5. When scanning the face and/or upper body areas, the eyes must be covered. If the patient is unable to wear eye protection, the face must not be scanned.
  6. Ensure that the room or space to be used for scanning has the correct laser warning labels and screening
  7. Ensure clean or sterilized eye protection is on hand for patient and staff if required.
  8. Angle the scan head downwards prior to turning on the moorLDI2-BI.
  9. Turn on the moorLDI2-BI.
  10. Enter Patient Information; use the Comment box for details of sickness, medication or any other factors which may influence peripheral blood flow.
  11. Plan to avoid scanning under direct sunlight, theatre lights or another bright lighting.
  12. Plan the scan head positions for all burn wounds. Consider scan directions that will avoid direct reflection of the moorLDI2-BI laser back into the scan head from moist wound surfaces.
Conditions
Laser Burn
Being tested
laser speckle contrast imaging device

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • laser speckle contrast imaging deviceOther

    laser speckle contrast imaging device will be used for measurement of burn wound depth en to be compared to the golden standard the laser doppler imaging device

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. primary outcome

    • To validate the LSCI device (Perimed AB, Järfälla, Sweden) in burn patients.

    Measured: 10 minutes

Secondary outcomes (1)
  1. secondary outcome

    • To validate a color code, comparing LDI (moorLDI2-Burn Imager™ (Moor Instruments, Axminster, United Kingdom) and LSCI in burn patients

    Measured: 10 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Sep 2021
  2. Study start15 Apr 2019
  3. Primary completion12 Mar 2020
  4. Study completion12 Mar 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05037916
Sponsor's protocol ID
L2019017 /NL66174.100.18
Acronym
COLA-B
Status last verified
Oct 2020
First submitted
13 Oct 2020
Last updated
8 Sep 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Laser Burn, run by Maasstad Hospital at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

primary outcome (time frame: 10 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in